Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2025Frontiers in ImmunologyOpen Access

The miRNA–immune axis in bladder cancer: systematic evidence for a new era of immunotherapy precision

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDaniel-Vasile DulfGRGloria RavegniniFGFederico M. Giorgi

Discussion

Loading...

Member takes

Overview

Systematic review uncovers miRNAs as potential biomarkers for immunotherapy response in bladder cancer, suggesting personalized treatment strategies.

Key Points

  • miRNAs shape the immune microenvironment of bladder cancer, influencing treatment responses and patient outcomes.
  • From 3,272 screened articles, 37 studies revealed miRNA involvement in immune cell infiltration and clinical outcomes.
  • Key miRNAs like miR-155 and miR-146b are linked to CD4 + memory T-cell and M1 macrophage infiltration in bladder cancer.
  • Further prospective studies are essential to apply miRNA insights into personalized immunotherapy strategies.

Cite This Study

Dulf et al. (2025) studied this question.

synapsesocial.com/papers/68d439f4713b0b5dfea79af7https://doi.org/10.3389/fimmu.2025.1639334
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive miRNA profiles revealing cancer-immunity2025
  2. 2Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability2025
  3. 3Urinary microRNAs as Prognostic Biomarkers for Predicting the Efficacy of Immune Checkpoint Inhibitors in Patients with Urothelial Carcinoma2025
  4. 4Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer2025
  5. 5Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomization analysis2025